https://www.curetoday.com/view/fda-approves-cavhanza-for-ph-positive-chronic-myeloid-leukemia
Jun 2, 2026 · The FDA has approved Cavhanza (nilotinib), a new orally disintegrating tablet formulation for adults with Philadelphia chromosome-positive chronic myeloid leukemia (
https://cyclepharma.com/news/cavhanza-nilotinib-orally-disintegrating-tablets-fda-approval/
Jun 2, 2026 · CAVHANZA (nilotinib) is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leuke
https://www.drugs.com/history/cavhanza.html
Jun 9, 2026 · Cavhanza (nilotinib) is a kinase inhibitor for use in the treatment of Philadelphia chromosome positive chronic myeloid leukemia. Cavhanza is indicated for the treat
https://novapharmanews.com/us/articles/fda-approves-oral-nilotinib-tablets-ph-cml
Jun 3, 2026 · FDA Approves Oral Nilotinib Tablets for Ph+ CML: A New Era for Treatment The FDA has approved oral nilotinib tablets, a significant advancement for patients with Phi
https://www.oncologynurseadvisor.com/news/fda-approves-cavhanza-nilotinib-chronic-myeloid-leukemia/
Jun 11, 2026 · Cavhanza, a BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of adults with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemi
https://www.oncnursingnews.com/view/fda-approves-oral-nilotinib-tablets-for-ph-cml
Jun 2, 2026 · The U.S. Food and Drug Administration (FDA) has approved Cavhanza, orally disintegrating nilotinib tablets, marking a significant shift in the management of Philadel
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217379Orig1s000ltr.pdf
The treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The treatment of adult patients with chro
https://www.targetedonc.com/view/fda-approves-nilotinib-with-no-mealtime-restrictions-in-ph-positive-cml
Nov 15, 2024 · The FDA granted approval to nilotinib (Danziten) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia
https://markets.financialcontent.com/stocks/article/bizwire-2026-6-2-cavhanza-nilotinib-orally-disintegrating-tablets-a-new-fda-approved-treatment-offering-ppi-and-h2ra-flexibility-for-ph-cml-patients1
Jun 2, 2026 · Indications CAVHANZA (nilotinib) is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic m
https://www.drugs.com/mtm/nilotinib.html
Jul 15, 2025 · Nilotinib is used in adults and children at least 1 year old to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (P